



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2159103 C 2002/03/12

(11)(21) **2 159 103**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1994/03/22
(87) Date publication PCT/PCT Publication Date: 1994/10/13
(45) Date de délivrance/Issue Date: 2002/03/12
(85) Entrée phase nationale/National Entry: 1995/09/25
(86) N° demande PCT/PCT Application No.: US 1994/003130
(87) N° publication PCT/PCT Publication No.: 1994/023069
(30) Priorité/Priority: 1993/03/26 (08/040,745) US

(51) Cl.Int.⁶/Int.Cl.⁶ C12Q 1/70, C12P 19/34, C12N 15/10,
C07H 21/00

(72) Inventeurs/Inventors:
Yang, Yeasing, US;
Ryder, Thomas B., US;
McDonough, Sherrol H., US

(73) Propriétaire/Owner:
GEN-PROBE INCORPORATED, US

(74) Agent: SMART & BIGGAR

(54) Titre : DETECTION DU VIRUS DE L'IMMUNODEFICIENCE HUMAINE DU TYPE 1
(54) Title: DETECTION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1

(57) Abrégé/Abstract:

Amplification oligonucleotides and hybridization assay probes which distinguish Human Immunodeficiency Virus type 1 from other viruses.



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12Q 1/70, C12P 19/34, C07H 21/04	A1	(11) International Publication Number: WO 94/23069 (43) International Publication Date: 13 October 1994 (13.10.94)
(21) International Application Number: PCT/US94/03130 (22) International Filing Date: 22 March 1994 (22.03.94) (30) Priority Data: 08/040,745 26 March 1993 (26.03.93) US (71) Applicant: GEN-PROBE INCORPORATED [US/US]; 9880 Campus Point Drive, San Diego, CA 92121 (US). (72) Inventors: McDONOUGH, Sherrol, H.; 5005 Maynard Street, San Diego, CA 92122 (US). RYDER, Thomas, B.; 1863 Angeles Glen, Escondido, CA 92029 (US). YANG, Yeasing; 13569 Glenclyff Way, San Diego, CA 92130 (US). (74) Agents: WARBURG, Richard J. et al.; Lyon & Lyon, 34th floor, 611 West Sixth Street, Los Angeles, CA 90017 (US).		(81) Designated States: AU, CA, JP, KR. Published 2159103 <i>With international search report.</i>
(54) Title: DETECTION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1		
(57) Abstract Amplification oligonucleotides and hybridization assay probes which distinguish Human Immunodeficiency Virus type 1 from other viruses.		

DESCRIPTIONDetection of Human Immunodeficiency Virus Type 1Field of the Invention

This invention relates to the design and construction of amplification oligonucleotides and probes to Human Immunodeficiency Virus Type 1 (HIV), which allow detection of the organism in a test sample.

Background of the Invention

10 This section provides a brief outline of relevant areas. None of the art cited or referred to is admitted to be prior art to the claims. Laboratory diagnosis of Human Immunodeficiency Virus Type 1 in humans is currently performed by demonstration of the presence of viral antigen (p24) or anti-HIV-1 antibodies in serum. Direct detection of viral DNA, however, is a more useful diagnostic tool in some populations, such as infants born to seropositive mothers. Detection of viral DNA is more rapid and less hazardous than culture. Direct hybridization lacks adequate sensitivity in most patients (Shaw et al. Science 226:1165-1171, 1984). Many
20 references mention oligonucleotides said to have use in detection of Human Immunodeficiency Virus. Most of these references also mention the use of polymerase chain reaction (PCR). These references include the following: Kwok et al., J. Virol. 61: 1690-1694, 1987; Agius et al., J. Virol. Meth., 30:141-150, 1990; Albert and Fenyo, J. Clin. Microbiol. 28:1560-1564, 1990; Bell and Ratner, AIDS Res. and Human

2159103

2

- Retroviruses 5:87-95, 1989; Bruisten et al., Vox Sang 61:24-29, 1991; Clarke et al., AIDS 4:1133-1136, 1990; Coutlee et al., Anal. Biochem. 181:96-105, 1989; Dahlen et al., J. Clin. Microbiol. 29:798-804, 1991; Dudding et al.,
- 5 Biochem. Biophys. Res. Comm. 167:244-250, 1990; Ferrer-Le-Coeur et al., Thrombosis and Haemostasis 65:478-482, 1991; Goswami et al., AIDS 5:797-803, 1991; Grankvist et al., AIDS 5:575-578, 1991; Guatelli et al., J. Virol. 64:4093-4098, 1990; Hart et al., Lancet 2 (8611):596-599, 1988;
- 10 Holland et al., Proc. Natl. Acad. Sci. USA, 88:7276-7280, 1991; Keller et al., Anal. Biochem. 177:27-32, 1989; Kumar et al., AIDS Res. and Human Retroviruses 5:345-354, 1989; Linz et al., J. Clin. Chem. Clin. Biochem. 28:5-13, 1990; Mano and Chermann, Res. Virol. 142:95-104, 1991; Mariotti
- 15 et al., AIDS 4:633-637, 1990; Mariotti et al., Transfusion 30:704-706, 1990; Meyerhans et al., Cell 58:901-910, 1989; Mousset et al., AIDS 4:1225-1230, 1990; Ou et al., Science 239:295-297, 1988; Pang et al., Nature 343:85-89, 1990; Paterlini et al., J. Med. Virol. 30:53-57, 1990; Perrin et
- 20 al., Blood 76:641-645, 1990; Preston et al., J. Virol. Meth. 33:383-390, 1991; Pritchard and Stefano, Ann. Biol. Clin. 48:492-497, 1990; Rudin et al., Eur. J. Clin. Microbiol. Infect. Dis. 10:146-156, 1991; Shoebridge et
- 25 al., AIDS 5:221-224, 1991; Stevenson et al., J. Virol. 64:3792-3803, 1990; Truckenmiller et al., Res. Immunol. 140:527-544, 1989; Van de Perre, et al., New Eng. J. Med. 325:593-598, 1991; Varas et al., BioTechniques 11:384-391, 1991; Velpandi et al., J. Virol. 65:4847-4852, 1991; Williams et al., AIDS 4:393-398, 1990; Zachar et al., J.
- 30 Virol. Meth. 33:391-395, 1991; Zack et al. Cell 61:213-222, 1990; Findlay et al., entitled "Nucleic acid test article and its use to detect a predetermined nucleic acid," PCT/US90/00452; Gingeras et al., entitled "Nucleic acid probe assay methods and compositions," PCT/US87/
- 35 01966; Brakel and Spadoro, entitled "Amplification capture assay," EPO application number 90124738.7, publication number 0 435 150 A2; Moncany and Montagnier, entitled

SUBSTITUTE SHEET (RULE 26)

2159103

3

"Séquences nucléotidiques issues du génome des rétrovirus du typ hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des génomes de ces rétrovirus et pour le diagnostic in-vitro des infections dues à ces virus," EPO application number 90401520.3, publication number 0 403 333 A2; Urdea, entitled "DNA-dependent RNA polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays," PCT/US91/00213; Musso et al., entitled "Lanthanide chelate-tagged nucleic acid probes," PCT/US88/03735; Chang, entitled "Cloning and expression of HTLV-III DNA," EPO application number 85307260.1, publication number 0 185 444 A2; and Levenson, entitled "Diagnostic kit and method using a solid phase capture means for detecting nucleic acids," EPO application number 89311862.0, publication number 0 370 694; and Sninsky et al., U.S. Patent No. 5,008,182.

Summary of the Invention

This invention discloses novel amplification oligonucleotides and detection probes for the detection of Human Immunodeficiency Virus Type 1. The probes are capable of distinguishing between the Human Immunodeficiency Virus type 1 and its known closest phylogenetic neighbors. The amplification oligonucleotides and probes may be used in an assay for the detection and/or quantitation of Human Immunodeficiency Virus nucleic acid.

It is known that a nucleic acid sequence able to hybridize to a nucleic acid sequence sought to be detected ("target sequence") can serve as a probe for the target sequence. The probe may be labelled with a detectable moiety such as a radioisotope, antigen or chemiluminescent moiety to facilitate detection of the target sequence. A background description of the use of nucleic acid hybridization as a procedure for the detection of particular nucleic acid sequences is provided in Kohne, U.S. Patent No. 4,851,330, and Hogan et al., EPO Patent Application

SUBSTITUTE SHEET (RULE 26)

2159103

4

No. PCT/US87/03009, entitled "Nucleic Acid Probes for Detection and/or Quantitation of Non-Viral Organisms."

It is also known that hybridization may occur between complementary nucleic acid strands including; DNA/DNA, DNA/RNA, and RNA/RNA. Two single strands of deoxyribo- ("DNA") or ribo- ("RNA") nucleic acid, formed from nucleotides (including the bases adenine (A), cytosine (C), thymidine (T), guanine (G), uracil (U), or inosine (I)), may hybridize to form a double-stranded structure in which the two strands are held together by hydrogen bonds between pairs of complementary bases. Generally, A is hydrogen bonded to T or U, while G is hydrogen bonded to C. At any point along the hybridized strands, therefore, one may find the classical base pairs AT or AU, TA or UA, GC, or CG. Thus, when a first single strand of nucleic acid contains sufficient contiguous complementary bases to a second, and those two strands are brought together under conditions which will promote their hybridization, double-stranded nucleic acid will result. Under appropriate conditions, DNA/DNA, RNA/DNA, or RNA/RNA hybrids may be formed. The present invention includes the use of probes or primers containing nucleotides differing in the sugar moiety, or otherwise chemically modified, which are able to hydrogen bond along the lines described above.

Thus, in a first aspect, the invention features hybridization assay probes able to distinguish Human Immunodeficiency Virus type 1 from other viruses found in human blood or tissues, and amplification oligonucleotides able to selectively amplify Human Immunodeficiency Virus nucleic acid. Specifically, the probes are nucleotide polymers which hybridize to the nucleic acid region of Human Immunodeficiency Virus type 1 corresponding to bases 763-793 of HIV type 1, (HXB2 isolate GenBank accession number K03455), or any of the regions corresponding to bases 1271-1301, 1358-1387, 1464-1489, 1501-1540, 1813-1845, 2969-2999, 3125-3161, 4148-4170, 4804-4832, 5950-5978, 9496-9523, 510-542, and 624-651; preferably, the

SUBSTITUTE SHEET (RULE 26)

2159103

5

oligonucleotide comprises, consists essentially of, or consists of the sequence (reading 5' to 3')

(SEQ ID NO: 1) GACTAGCGGAGGCTAGAAAGGAGAGAGATGGG
(SEQ ID NO: 2) GAAGGCTTTCAGCCCAGAAGTAATACCCATG
5 (SEQ ID NO: 3) ATTTGCATGGCTGCTTGATGTCCCCCCTACT
(SEQ ID NO: 4) CTTCCCCTTGGTTCTCTCATCTGGCC
(SEQ ID NO: 5) GTCATCCATCCTATTTGTTCTGAAGGGTACTAGTAG
(SEQ ID NO: 6) CTCCCTGACATGCTGTCATCATTTCTTCTAGTG
(SEQ ID NO: 7) GTGGAAGCACATTGTACTGATATCTAATCCC
10 (SEQ ID NO: 8) GCTCCTCTATTTTTTGTCTATGCTGCCCTATTTCTAA
(SEQ ID NO: 9) CCTTTGTGTGCTGGTACCCATGC
(SEQ ID NO: 10) CTACTATTCTTTCCCCTGCACTGTACCCC
(SEQ ID NO: 11) AAAGCCTTAGGCATCTCCTATGGCAGGAA
(SEQ ID NO: 12) GCAGCTGCTTATATGCAGGATCTGAGGG
15 (SEQ ID NO: 13) CAAGGCAAGCTTTATTGAGGCTTAAGCAGTGGG
(SEQ ID NO: 14) ATCTCTAGCAGTGGCGCCCGAACAGGGA

or RNA equivalents thereto (SEQ. ID. Nos. 67-80), or oligonucleotides complementary thereto (SEQ. ID. Nos. 53-66), or RNA equivalents to the oligonucleotides
20 complementary thereto (SEQ. ID. Nos. 81-94).

The oligonucleotides are used with or without a helper probe as described below. The use of helper probes (e.g., SEQ. ID. Nos. 15-18) and complementary oligonucleotides to the helper probes (e.g., SEQ. ID. Nos.
25 95-98) and RNA equivalents thereto (e.g., SEQ. ID. Nos. 132-140) enhances nucleic acid hybridization.

By "consists essentially of" is meant that the probe is provided as a purified nucleic acid which under stringent hybridizing conditions hybridizes with the
30 target sequence and not with other related target sequences present in either other virus nucleic acids or human nucleic acids. Such a probe may be linked to other nucleic acids which do not affect such hybridization. Generally, it is preferred that the probe is between 15 to
35 100 (most preferably between 20 and 50) bases in size. It may, however, be provided in a vector.

SUBSTITUTE SHEET (RULE 26)

2159103 6

In a related aspect, the invention features the formation of nucleic acid hybrids formed by the hybridization of the probes of this invention with target nucleic acid under stringent hybridization conditions. Stringent hybridization conditions involve the use 0.05 M lithium succinate buffer containing 0.6 M LiCl at 60°C. The hybrids are useful because they allow the specific detection of viral nucleic acid.

In another related aspect, the invention features amplification oligonucleotides useful for specific detection of Human Immunodeficiency Virus type 1 in an amplification assay. The amplification oligonucleotides are complementary to conserved regions of HIV genomic nucleic acid and are nucleotide polymers able to hybridize to regions of the nucleic acid of HIV corresponding to HIV-1 HXB2R bases 682-705, 800-822, 1307-1337, 1306-1330, 1315-1340, 1395-1425, 1510-1535, 1549-1572, 1743-1771, 1972-1989, 2868-2889, 3008-3042, 3092-3124, 3209-3235, 4052-4079, 4176-4209, 4169-4206, 4394-4428, 4756-4778, 4835-4857, 4952-4969, 5834-5860, 5979-5999, 9431-9457, 9529-9555, 449-473, 550-577, 578-601, 579-600, 624-646, and 680-703.

Specifically, such amplification oligonucleotides consist, comprise, or consist essentially of those selected from (reading 5' to 3'):

- (X)CTCGACGCAGGACTCGGCTTGCTG (SEQ. ID. NO. 19),
- (X)CTCCCCCGCTTAATACTGACGCT (SEQ. ID. NO. 20),
- (X)GGCAAATGGTACATCAGGCCATATCACCTAG (SEQ. ID. NO. 21),
- (X)GGGGTGGCTCCTTCTGATAATGCTG (SEQ. ID. NO. 22),
- 30 (X)CAGAAGGAGCCACCCCAAGATTTA (SEQ. ID. NO. 23),
- (X)GACCATCAATGAGGAAGCTGCAGAATG (SEQ. ID. NO. 24),
- (X)CCCATTCTGCAGCTTCCTCATTGAT (SEQ. ID. NO. 25),
- (X)AGTGACATAGCAGGAATA (SEQ. ID. NO. 26),
- (X)CCATCCTATTTGTTCTGAAGGGTAC (SEQ. ID. NO. 27),
- 35 (X)AGATTTCTCCTACTGGGATAGGT (SEQ. ID. NO. 28),
- (X)GAAACCTTGTTGAGTCCAAAATGCGAACCC (SEQ. ID. NO. 29),
- (X)TGTGCCCTTCTTTGCCAC (SEQ. ID. NO. 30),

- (X) CAGTACTGGATGTGGGTGATGC (SEQ. ID. NO. 31),
 (X) GTCATGCTACTTTGGAATATTTCTGGTGATCCTTT (SEQ. ID. NO. 32),
 (X) CAATACATGGATGATTTGTATGTAGGATCTGAC (SEQ. ID. NO. 33),
 (X) ACCAAAGGAATGGAGGTTCTTTCTGATG (SEQ. ID. NO. 34),
 5 (X) GCATTAGGAATCATTCAAGCACAACCAG (SEQ. ID. NO. 35),
 (X) GCACTGACTAATTTATCTACTTGTTTCATTTCTC (SEQ. ID. NO. 36),
 (X) GGGATTGGAGGAAATGAACAAGTAGATAAATTAGTCAG (SEQ. ID. NO. 37),
 (X) TGTGTACAATCTAGTTGCCATATTCCTGGACTACA (SEQ. ID. NO. 38),
 10 (X) CAAATGGCAGTATTCATCCACA (SEQ. ID. NO. 39),
 (X) GTTTGTATGTCTGTTGCTATTAT (SEQ. ID. NO. 40),
 (X) CCCTTCACCTTTCCAGAG (SEQ. ID. NO. 41),
 (X) GAGCCCTGGAAGCATCCAGGAAGTCAG (SEQ. ID. NO. 42),
 (X) CTTGTCGCTGTCTCCGCTTC (SEQ. ID. NO. 43),
 15 (X) CAAGGGACTTTCCGCTGGGGACTTTCC (SEQ. ID. NO. 44),
 (X) GTCTAACCAGAGAGACCCAGTACAGGC (SEQ. ID. NO. 45),
 (X) GTACTGGGTCTCTCTGGTTAGACCA (SEQ. ID. NO. 46),
 (X) CACACAACAGACGGGCACACACTACTTG (SEQ. ID. NO. 47),
 (X) CTGAGGGATCTCTAGTTACCAGAGT (SEQ. ID. NO. 48),
 20 (X) CTCTGGTAACTAGAGATCCCTCA (SEQ. ID. NO. 49),
 (X) GTTCGGGCGCCACTGCTAGAGAT (SEQ. ID. NO. 50),
 (X) GCAAGCCGAGTCCTGCGTCGAGA (SEQ. ID. NO. 51)

and the RNA equivalents thereto (SEQ. ID. Nos. 99-131).

- Where (X) is nothing or a 5' oligonucleotide sequence that
 25 is recognized by an enzyme, including but not limited to
 the promoter sequence for T7, T3, or SP6 RNA polymerase,
 which enhances initiation or elongation of RNA
 transcription by an RNA polymerase. One example of X
 includes the sequence SEQ. ID. NO. 52:

- 30 5'-AATTTAATACGACTCACTATAGGGAGA-3'.

These amplification oligonucleotides are used in a
 nucleic acid amplification assay such as the polymerase
 chain reaction or an amplification reaction using RNA
 polymerase, DNA polymerase and RNase H or its equivalent,
 35 as described by Kacian and Fultz, supra, and by Sninsky et
 al. US. Patent No. 5,079,351.

2159103

8

The amplification oligonucleotides and probes of this invention offer a rapid, non-subjective method of identification and quantitation of a sample for specific sequences unique to strains of Human Immunodeficiency Virus type 1.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Description of the Preferred Embodiments

We have discovered particularly useful DNA probes complementary to particular nucleic acid sequences of Human Immunodeficiency Virus type 1. Furthermore, we have successfully used these probes in a specific assay for the detection of Human Immunodeficiency Virus type 1, distinguishing it from the known and presumably most closely related taxonomic or phylogenetic neighbors found in human blood or tissues.

We have also identified particularly useful amplification oligonucleotides which are complementary to the Human Immunodeficiency Virus type 1 nucleic acid, and have used these oligonucleotides, e.g., as primers or promoter primer combinations (i.e., a primer having a promoter sequence attached), to amplify the nucleic acid of Human Immunodeficiency Virus, allowing its direct detection in a sample.

Useful guidelines for designing amplification oligonucleotides and probes with desired characteristics are described herein. The optimal sites for amplifying and probing contain two, and preferably three, conserved regions greater than about 15 bases in length, within about 350 bases, and preferably within 150 bases, of contiguous sequence. The degree of amplification observed with a set of primers or promotor/primers depends on several factors, including the ability of the oligonucleotides to hybridize to their complementary sequences and their ability to be extended enzymatically. Because

the extent and specificity of hybridization reactions are affected by a number of factors, manipulation of those factors will determine the exact sensitivity and specificity of a particular oligonucleotide, whether perfectly complementary to its target or not. The importance and effect of various assay conditions are known to those skilled in the art as described in Hogan et al., EPO Patent Application No. PCT/US87/03009, entitled "Nucleic Acid Probes for Detection and/or Quantitation of Non-Viral Organisms".

10 The length of the target nucleic acid sequence and, accordingly, the length of the probe sequence can be important. In some cases, there may be several sequences from a particular region, varying in location and length, which will yield probes with the desired hybridization characteristics. In other cases, one sequence may be significantly better than another which differs merely by a single base. While it is possible for nucleic acids that are not perfectly complementary to hybridize, the longest stretch of perfectly homologous base sequence will normally primarily
20 determine hybrid stability. While oligonucleotide probes of different lengths and base composition may be used, oligonucleotide probes preferred in this invention are between about 10 to 50 bases in length and are sufficiently homologous to the target nucleic acid to hybridize under stringent hybridization conditions. We have found that optimal primers have target-binding regions of 18-38 bases, with a predicted T_m (melting temperature) to target of about 65°C.

2159103
9a

Amplification oligonucleotides or probes should be positioned so as to minimize the stability of the oligomer:nontarget (i.e., nucleic acid with similar sequence to target nucleic acid) nucleic acid hybrid. It is preferred that the amplification oligomers and

2159103

10

detection probes are able to distinguish between target and non-target sequences. In designing probes, the differences in these T_m values should be as large as possible (e.g., at least 2°C and preferably 5°C).

5 Regions of the nucleic acid which are known to form strong internal structures inhibitory to hybridization are less preferred. Examples of such structures include hairpin loops. Likewise, probes with extensive self-complementarity should be avoided.

10 The degree of non-specific extension (primer-dimer or non-target copying) can also affect amplification efficiency, therefore primers are selected to have low self- or cross- complementarity, particularly at the 3' ends of the sequence. Long homopolymer tracts and high GC
15 content are avoided to reduce spurious primer extension. Commercial computer programs are available to aid in this aspect of the design. Available computer programs include MacDNASIS™ 2.0 (Hitachi Software Engineering American Ltd.) and OLIGO® ver. 4.1 (National Bioscience).

20 Hybridization is the association of two single strands of complementary nucleic acid to form a hydrogen bonded double strand. It is implicit that if one of the two strands is wholly or partially involved in a hybrid that it will be less able to participate in formation of
25 a new hybrid. By designing a probe so that a substantial portion of the sequence of interest is single stranded, the rate and extent of hybridization may be greatly increased. If the target is an integrated genomic sequence then it will naturally occur in a double stranded
30 form, as is the case with the product of the polymerase chain reaction (PCR). These double-stranded targets are naturally inhibitory to hybridization with a probe and require denaturation prior to the hybridization step. Finally, there can be intramolecular and intermolecular
35 hybrids formed within a probe if there is sufficient self complementarity. Such structures can be avoided through careful probe design. Commercial computer programs are

SUBSTITUTE SHEET (RULE 26)

2159103

11

available to search for this type of interaction. Available computer programs include MacDNASIS™ 2.0 (Hitachi Software Engineering American Ltd.) and OLIGO® ver. 4.1 (National Bioscience).

5 Once synthesized, selected oligonucleotide probes may be labelled by any of several well known methods. 2 J. Sambrook, E.F. Fritsch and T. Maniatis, Molecular Cloning 11 (2d ed. 1989). Useful labels include radio-isotopes as well as non-radioactive reporting groups. We 10 currently prefer to use acridinium esters.

 Oligonucleotide/target hybrid melting temperature may be determined by isotopic methods well known to those skilled in the art. It should be noted that the T_m for a given hybrid will vary depending on the hybridization 15 solution being used. Sambrook, et al. supra.

 Rate of hybridization may be measured by determining the C_0t_x . The rate at which a probe hybridizes to its target is a measure of the thermal stability of the target secondary structure in the probe region. The standard 20 measurement of hybridization rate is the C_0t_x which is measured as moles of nucleotide per liter times seconds. Thus, it is the concentration of probe times the time at which 50% of maximal hybridization occurs at that concentration. This value is determined by hybridizing 25 various amounts of probe to a constant amount of target for a fixed time. The C_0t_x is found graphically by standard procedure.

 The following examples set forth oligonucleotide probes complementary to a unique nucleic acid sequence 30 from a target organism, and their use in a hybridization assay.

Examples:

 Probes specific for Human Immunodeficiency Virus type 1 were identified by comparison of sequences obtained from 35 the published database GenBank. Sequences ID Nos. 1-12 were characterized and shown to be specific for Human

SUBSTITUTE SHEET (RULE 26)

Immunodeficiency Virus type 1. Phylogenetically near neighbors including Human Immunodeficiency Virus type 2, Human T-cell Leukemia Virus type 1 and Human T-Cell Leukemia Virus type 2 were used as comparisons with the
5 sequence of Human Immunodeficiency Virus Type 1.

Example 1. Probes for HIV

A hybridization protection assay was used to demonstrate the reactivity and specificity of the probes for Human Immunodeficiency Virus type 1. The probes were
10 first synthesized with a non-nucleotide linker, then labelled with a chemiluminescent acridinium ester (AE) as described by Arnold, et al., PCT/US88/03361, entitled "Acridinium Ester Labeling and Purification of Nucleotide Probes," . The
15 acridinium ester attached to an unhybridized probe is susceptible to hydrolysis and rendered non-chemiluminescent under mild alkaline conditions. However, the acridinium ester attached to hybridized probe is relatively resistant to hydrolysis. Thus, it is possible
20 to assay for hybridization of acridinium ester-labelled probe by incubation with an alkaline buffer, followed by detection of chemiluminescence in a luminometer. Results are given in Relative Light Units (RLU); the quantity of photons emitted by the labelled-probe measured by the
25 luminometer.

In the following experiment, DNA prepared from clones containing full or partial sequences of the target viruses was assayed. An example of a method for preparing the DNA from clones is provided by Sambrook et al, supra. The
30 source of DNA for the clones was as follows; Human Immunodeficiency Virus type 1, BH10 (L. Ratner et al., Nature 312:277-284. 1985); Human Immunodeficiency Virus type 2 NIHZ (J.F. Zagury, et al., Proc. Natl. Acad. Sci. USA 85:5941-5945. 1988), Human T-cell leukemia virus type
35 1 pMT-2, (M. Clarke et al. Nature 305:60-62. 1983); Human T-cell leukemia virus type 2 (K. Shimotohmo et al. Proc.

Natl. Acad. Sci. USA 82:3101-3105. 1985); and Human Hepatitis B Virus serotype ADW, obtained from ATCC(# 45020). Target in 50 μ l of 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), 10 mM ethylenediaminetetraacetic acid (EDTA), 1% lithium lauryl sulfate, 5 pH 7.4, was denatured at 95°C for 5 min, cooled on wet ice, and 0.04 pmol of probe in 50 μ l of 0.1 M lithium succinate buffer, pH 4.7, 2% (w/v) lithium lauryl sulfate, 1.2 M lithium chloride, 10 mM EDTA and 20 mM 10 ethyleneglycol-bis-(beta-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA) was added. Hybridization was carried out at 60°C for 10 min, followed by addition of 300 μ l of 0.6 M sodium borate pH 8.5, 1% Triton X-100* and a second incubation at 60°C for 6 min to hydrolyze the AE 15 on unhybridized probe. Samples were cooled in ice water for 1 min, placed at room temperature for another 3 min, and then analyzed in a LEADER 1 luminometer equipped with automatic injection of detection reagent I (containing 0.1% hydrogen peroxide and 1 mM nitric acid) and detection 20 reagent II (containing 1 N sodium hydroxide and a surfactant component). Some of the hybridization reactions were enhanced with the addition of 4 pmol of unlabelled "helper probe" as disclosed in Hogan et al., U.S. Patent No. 5,030,557 entitled "Means and Methods for 25 Enhancing Nucleic Acid Hybridization".

An RLU value greater than 5,000 RLU was a positive result; less than 5,000 RLU was a negative result.

The following data (Table 1) show that the probes do 30 not cross react with viral DNA from closely related viruses found in human blood or tissues. The samples also gave a positive signal when tested with a probe specific to each target, thereby confirming sample adequacy.

*Trade-mark

2159103

14

Table 1. Hybridization Assay with HIV-1 probes.

Target :		1	2	3	4	5	6	7
Probe								
Sequence								
5	ID No:							
	1	179,166	482	500	496	190	496	470
	2	14,992	563	394	377	409	383	465
	4	61,691	2,818	750	695	686	702	642
	6	28,038	546	408	375	356	369	372
10	7	27,407	640	401	252	366	343	359
	8	45,868	1,432	395	392	386	401	404
	9	15,971	721	280	268	261	274	284
	10	59,007	714	264	280	284	272	567
	11	25,856	4,641	3,598	3,736	3,711	3,855	3,388
15	12	140,691	1,846	602	694	531	534	1,236

Target 1 = HIV-1 BH10 isolate 9 Kb SstI fragment, Target 2 = Human Immunodeficiency Virus Type 2 (NIHZ isolate) 9 Kb NaeI fragment, Target 3 = Human T-cell leukemia virus type 1 (pMT-2) 5' 4.6 Kb SstI-BamHI fragment; Target 4 = Human T-cell leukemia virus type 1 3' 4.4 Kb XbaI-SstI fragment, Target 5 = Human T-cell leukemia virus type 2 3.5 Kb BamHI fragment, Target 6 = Human T-cell leukemia virus type 2 5 Kb BamHI fragment, Target 7 = Human Hepatitis B virus serotype ADW 1.3, 1.8 Kb BamHI fragments.

The above data confirm that the novel probes herein disclosed and claimed are capable of distinguishing Human Immunodeficiency Virus type 1 from these viruses found in human blood.

30 Example 2. Amplification of HIV by PCR

To demonstrate the reactivity of the primers and probes for Human Immunodeficiency Virus type 1, the following experiment was performed. Zero, 20, or 100 copies of plasmid DNA containing Human Immunodeficiency Virus DNA was linearized with a restriction endonuclease, and added to amplification reactions containing 50 pmol of

SUBSTITUTE SHEET (RULE 26)

2159103

15

each primer, 10 mM Tris HCl pH 8, 50 mM KCl, 1.25 mM MgCl₂, 0.25 mM each of dATP, dTTP, dCTP, dGTP, and 2.5 U Taq DNA polymerase in 50 µl. The reactions were incubated at 95°C for 1-2 min, and then cycled 35 times at 55°C for 15 sec, 5 72°C for 30 sec, and 95°C for 20 sec in a Perkin-Elmer 9600 thermocycler or 55°C for 30 sec, 72°C for 60 sec, and 95°C for 60 sec in a Perkin-Elmer 48 well thermocycler. Following cycling, the reactions were incubated at 72°C for 6-7 min and stored at 4°C. Ten µl of the product was 10 analyzed by hybridization protection assay with 0.04 pmol of labeled probe. The data are shown in Table 2. RLU greater than 7,000 is considered a positive result.

Table 2. Amplification of Human Immunodeficiency Virus Type 1 by PCR

15	Primer Sequence ID Nos:	Probe Sequence ID. No.	Sample		
			0 c	20 c	RLU 100 c
20	19/20*	1	886	827,202	723,008
	21/22*	2	2,677	24,030	48,521
	*23/25	3	370	144,082	603,456
	*24/27	4	4,042	81,052	163,355
	*26/28	5	263	273,023	593,022
25	*29/30	6	1,008	328,736	366,590
	*31/32	7	3,394	73,690	86,168
	*33/34	8	1,648	7,152	24,027
	*35/36	9	560	82,980	145,681
	*39/40	10	810	279,079	299,815
30	*39/41	10	886	362,914	427,500
	42/43*	11	5,830	680,788	1,939,372
	*44/45	12	1,387	21,428	130,709

The starred (*) primers had the sequence 5'-AATTTAATACGACTCACTATAGGGAGA-3' attached to the 5' end of 35 the primer. 0 c = 0 copies of HIV DNA, 20 c = 20 copies of HIV DNA, 100 c = 100 copies of HIV DNA. Probe 1 was

SUBSTITUTE SHEET (RULE 26)

used in the presence of unlabeled helper probe SEQ. ID. No. 15. Probe 7 was used in the presence unlabeled helper probe SEQ. ID. No. 16. Probe 10 was used in the presence of unlabeled helper probe SEQ. ID. No. 17. Probe 12 was used in the presence of unlabeled helper probe SEQ. ID. No. 18. As the copy number increased, RLU increased. Thus, the primers of the present invention were able to successfully amplify, by PCR, HIV type 1 target sequences which were detected using the probes of the present invention.

10 Example 3. Patient samples

In this example, patient samples containing lysate prepared from 200,000 Ficoll-Hypaque* purified white blood cells from individuals known to be infected with HIV type 1 or an individual not infected with HIV type 1 (negative) were analyzed as described in Example 2. These cells were prepared as described in Ryder and Kacian, entitled "Preparation of nucleic acid from blood," Canadian Patent Application No. 2,137,690 filed 11 June 1993, also WO 93/25711. The results are shown in Table 3.

*Trade-mark

Table 3. PCR Assay

		Sample		
		RLU		
		Patient 1	Patient 2	Negative
Primer	Probe			
Sequence	Sequence			
ID Nos:	ID. No.			
19/20*	1	27,616	71,981	886
21/22*	2	34,949	35,483	565
*23/25	3	45,230	93,529	455
10 *24/27	4	2,355	25,329	1,052
*26/28	5	22,345	26,014	369
*31/32	7	200,418	130,486	481
*33/34	8	43,993	40,389	705
*39/40	10	36,310	50,838	976
*39/41	10	55,582	98,504	993

2159103

17

Table 3. PCR Assay (Cont'd)

		Sample		RLU
		Patient 1	Patient 2	Negative
Primer	Probe			
5 Sequence	Sequence			
ID Nos:	ID. No.			
42/43*	11	99,028	207,605	6,057
*44/45	12	55,082	80,388	1,496
The starred (*) primers had the sequence 5'-				
10	AATTTAATACGACTCACTATAGGGAGA-3' attached to the 5' end of			
the primer. The primers of the present invention were				
able to amplify by PCR HIV type 1 target sequences present				
in individuals infected with HIV. The amplified target				
sequences were detected by the probes of the present				
15	invention. Thus, individuals containing HIV type 1 and an			
individual not containing HIV type 1 were correctly				
identified.				

Example 4. Non-PCR Amplification

To show that the amplification oligomers also work in

20 a transcription based amplification assay, 0, 2,000, or 20,000 copies of plasmid DNA containing HIV type 1 was linearized using a restriction endonuclease, and heated to 95°C for two min and cooled to 37°C for 1 min. Following addition of 800 U of MMLV reverse transcriptase the

25 reactions were incubated for 12 min at 37°C, heated to 95°C for two min, and cooled to 37°C for one min. 800 U of MMLV reverse transcriptase and 400 U of T7 RNA polymerase were added and the reactions were incubated for 3 hr at 37°C. The final amplification conditions were 70

30 mM Tris HCl, pH 8, 35 mM KCl, 15 mM KOH neutralized N-acetyl-cysteine, 6 mM rGTP, 4 mM rCTP, 4 mM rATP, 4 mM rUTP, 1 mM each of dTTP, dATP, dCTP and dGTP, and 22 mM MgCl₂ in 100 µl. Ten µl of each reaction was mixed with 40 µl of water and assayed as described for Table 1 except

35 that the hybridization buffer contained 20 mM aldrithiol. The results in RLU are shown in Table 4.

SUBSTITUTE SHEET (RULE 26)

2159103

18

Table 4. Transcription-Based Amplification Assay

		RLU		
Primers	Probe	0 c	2,000 c	20,000 c
Sequence	Sequence			
5 ID Nos:	ID. No.			
19/20*	1	681	24,170	190,536
21/22*	2	793	62,476	523,770
*23/25	3	2,239	812,577	1,126,045
*24/27	4	1,901	160,274	780,351
10 *26/28	5	2,555	877,893	1,167,756
*29/30	6	868	299,255	880,119
*31/32	7	871	129,732	969,034
*33/34	8	710	134,887	986,266
*35/36	9	884	128,981	1,021,865
15 *39/40	10	1,597	375,629	478,883
*39/41	10	1,264	499,304	495,509
*44/45	12	2,426	41,684	542,339

The starred (*) primers had the sequence 5'-AATTTAATACGACTCACTATAGGGAGA-3' attached to the 5' end of the primer. Probe 1 was used in the presence of unlabelled helper probe SEQ. ID. No. 15. Probe 7 was used in the presence of unlabelled helper probe SEQ. ID. No. 16, probe 10 was used in the presence of unlabelled helper probe SEQ. ID. No. 17, and probe 12 was used in the presence of unlabelled helper probe SEQ. ID. No. 18. 0 c = 0 copies of HIV DNA, 2,000 c = 2,000 copies of HIV DNA, 20,000 c = 20,000 copies of HIV DNA.

As the copy number increased RLU also increased. Thus, the primers of the present invention can be used to amplify HIV type 1 target sequences using a transcription based amplification assay and the amplified target sequences can be detected using the probes of the present invention.

Example 5.

This example demonstrates the ability of probes for Human Immunodeficiency Virus type 1 to detect low levels

SUBSTITUTE SHEET (RULE 26)

2159103

19

of target oligomer produced in a transcription based amplification assay. Zero or 10 copies of plasmid DNA containing HIV type I sequence was linearized using a restriction endonuclease, heated in the presence of 1 μ g of human DNA to 95°C for eight minutes, and then cooled to 42°C for six minutes. Amplification was carried out at 42°C for two hours using 800 U MMLV reverse transcriptase and 400 U of T7 RNA polymerase, in the following reaction mix: 50 mM Tris HCl pH 8, 17.5 mM MgCl₂, 0.05 mM zinc acetate, 10% glycerol, 6.25 mM rGTP, 2.5 mM rCTP, 6.25 mM rATP, 2.5 mM rUTP, 0.2 mM dTTP, 0.2 mM dATP, 0.2 mM, 0.2 mM dCTP and 0.2 mM dGTP. Primer SEQ ID NOs. 26, 28, and 41 were used at a concentration of 30 pmol, primer SEQ ID NO. 39 was used at a concentration of 15 pmol. The entire reaction was analyzed using the hybridization protection assay with 0.04 pmol of probe in 100 μ l of the hybridization buffer (supplemented with 20 mM aldrithiol) as described in Example 1. Probe SEQ ID NO. 10 was hybridized in the presence of 2 pmol unlabeled helper SEQ ID NO. 17.

Table 5. Low Level Transcription-Based Amplification Assay

		RLU	
Primers SEQ	Probe SEQ	0 copies	10 copies
25 ID NOs.			
*26/28	5	1,293	64,639
*39/40	10	2,143	564,185
The 10 copy values represent the average of ten replicates. The starred (*) primers had the sequence 5'-			
30 AATTTAATACGACTCACTATAGGGAGA-3'			
attached to the 5' end of the primer.			

Other embodiments are within the following claims.

SUBSTITUTE SHEET (RULE 26)

2159103

20

(1) GENERAL INFORMATION:

(i) APPLICANT: Sherrol H. McDonough, Thomas B. Ryder,
Yeasing Yang

5 (ii) TITLE OF INVENTION: NUCLEIC ACID AMPLIFICATION
OLIGONUCLEOTIDES AND PROBES
TO HUMAN IMMUNODEFICIENCY
VIRUS TYPE 1

(iii) NUMBER OF SEQUENCES: 140

(iv) CORRESPONDENCE ADDRESS:

10 (A) ADDRESSEE: Lyon & Lyon
(B) STREET: 611 West Sixth Street
(C) CITY: Los Angeles
(D) STATE: California
(E) COUNTRY: USA
15 (F) ZIP: 90017

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
(B) COMPUTER: IBM PS/2 Model 50Z or 55SX
(C) OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)
20 (D) SOFTWARE: WordPerfect (Version 5.0)

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

25 (vii) PRIOR APPLICATION DATA:

Prior applications total, including application described
below: 2

(A) APPLICATION NUMBER: U.S. Serial No. 07/550,837
(B) FILING DATE: 7/10/90
30 (A) APPLICATION NUMBER: U.S. Serial No. 07/379,501
(B) FILING DATE: 7/11/89

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Warburg, Richard J.
(B) REGISTRATION NUMBER: 32,327
35 (C) REFERENCE/DOCKET NUMBER: 196/189

SUBSTITUTE SHEET (RULE 26)

2159103

21

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (213) 489-1600
(B) TELEFAX: (213) 955-0440
(C) TELEX: 67-3510

5 (2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
10 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GACTAGCGGA GGCTAGAAGG AGAGAGATGG G 31

(3) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 31
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

20 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 2:

GAAGGCTTTC AGCCCAGAAG TAATACCCAT G 31

(4) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 30
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 3:

ATTGTCATGG CTGCTTGATG TCCCCCCT 30

30 (5) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 26
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 4:

CTTCCCCTTG GTTCTCTCAT CTGGCC 26

SUBSTITUTE SHEET (RULE 26)

2159103

22

(6) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 37
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 5:

GTCATCCATC CTATTTGTTC CTGAAGGGTA CTAGTAG 37

(7) INFORMATION FOR SEQ ID NO: 6:

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 6:

CTCCCTGACA TGCTGTCATC ATTTCTTCTA GTG 33

(8) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 31
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 7:

GTGGAAGCAC ATTGTACTGA TATCTAATCC C 31

25 (9) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 37
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 8:

GCTCCTCTAT TTTTGTCTA TGCTGCCCTA TTTCTAA 37

(10) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 23
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

SUBSTITUTE SHEET (RULE 26)

2159103

23

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 9:
 CCTTTGTGTG CTGGTACCCA TGC 23

(11) INFORMATION FOR SEQ ID NO: 10:

5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

10 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 10:
 CTACTATTCT TTCCCCTGCA CTGTACCCC 29

(12) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29

15 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 11:
 AAAGCCTTAG GCATCTCCTA TGGCAGGAA 29

20 (13) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

25 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 12:
 GCAGCTGCTT ATATGCAGGA TCTGAGGG 28

(14) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 33

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 13:
 35 CAAGGCAAGC TTTATTGAGG CTTAAGCAGT GGG 33

(15) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

SUBSTITUTE SHEET (RULE 26)

2159103

24

(A) LENGTH: 28
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 14:
ATCTCTAGCA GTGGCGCCCG AACAGGGA 28

(16) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 24
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 15:
TGCGAGAGCG TCAGTATTAA GCGG 24

15 (17) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
20 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 16:
CTACTTTGGA ATATTGCTGG TGATCCTTTC CATCCC 36

(18) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 33
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 17:
30 CCAATCCCCC CTTTCTTTT AAAATTGTGG ATG 33

(19) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24
(B) TYPE: nucleic acid
35 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

SUBSTITUTE SHEET (RULE 26)

2159103

25

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 18:

CTCGCCACTC CCCAGTCCCG CCCA 24

(20) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 24
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 19:

10 CTCGACGCAG GACTCGGCTT GCTG 24

(21) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 23
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 20:

CTCCCCCGCT TAATACTGAC GCT 23

(22) INFORMATION FOR SEQ ID NO: 21:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 21:

GGCAAATGGT ACATCAGGCC ATATCACCTA G 31

(23) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 25
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 22:

GGGGTGGCTC CTTCTGATAA TGCTG 25

35 (24) INFORMATION FOR SEQ ID NO: 23:

SUBSTITUTE SHEET (RULE 26)

2159103

26

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 5 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 23:

CAGAAGGAGC CACCCACAA GATTTA 26

(25) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 27
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 24:

15 GACCATCAAT GAGGAAGCTG CAGAATG 27

(26) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25
 (B) TYPE: nucleic acid
 20 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 25:

CCCATCTGC AGCTTCCTCA TTGAT 25

(27) INFORMATION FOR SEQ ID NO: 26:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

30 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 26:

AGTGACATAG CAGGAATA 19

(28) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26
 35 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

SUBSTITUTE SHEET (RULE 26)

2159103

27

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 27:
 CCATCCTATT TGTTCCTGAA GGTAC 26

(29) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 23
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 28:

10 AGATTTCTCC TACTGGGATA GGT 23

(30) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30
 (B) TYPE: nucleic acid
 15 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 29:

GAAACCTTGT TGAGTCCAAA ATGCGAACCC 30

(31) INFORMATION FOR SEQ ID NO: 30:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

25 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 30:

TGTGCCCTTC TTTGCCAC 18

(32) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22
 30 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 31:

CAGTACTGGA TGTGGGTGAT GC 22

35 (33) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

SUBSTITUTE SHEET (RULE 26)

2159103

28

(A) LENGTH: 35
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

5 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 32:
 GTCATGCTAC TTTGGAATAT TTCTGGTGAT CCTTT 35

(34) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33
 10 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 33:
 CAATACATGG ATGATTTGTA TGTAGGATCT GAC 33

15 (35) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 20 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 34:
 ACCAAAGGAA TGGAGGTTCT TTCTGATG 28

(36) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 28
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 35:
 30 GCATTAGGAA TCATTCAAGC ACAACCAG 28

(37) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34
 (B) TYPE: nucleic acid
 35 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 36:

SUBSTITUTE SHEET (RULE 26)

2159103

29

GCACTGACTA ATTTATCTAC TTGTTTCATTT CCTC 34

(38) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 38
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 37:

GGGATTGGAG GAAATGAACA AGTAGATAAA TTAGTCAG 38

10 (39) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 35
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 38:

TGTGTACAAT CTAGTTGCCA TATTCCTGGA CTACA 35

(40) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 22
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 39:

25 CAAATGGCAG TATTCATCCA CA 22

(41) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 23
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 40:

GTTTGTATGT CTGTTGCTAT TAT 23

(42) INFORMATION FOR SEQ ID NO: 41:

35 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18
 (B) TYPE: nucleic acid

SUBSTITUTE SHEET (RULE 26)

2159103

30

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 41:

CCCTTCACCT TTCCAGAG 18

5 (43) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 42:

GAGCCCTGGA AGCATCCAGG AAGTCAG 27

(44) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 43:

20 CTTCGTCGCT GTCTCCGCTT C 21

(45) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: nucleic acid

25 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 44:

CAAGGGACTT TCCGCTGGGG ACTTTCC 27

(46) INFORMATION FOR SEQ ID NO: 45:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

35 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 45:

GTCTAACCAG AGAGACCCAG TACAGGC 27

SUBSTITUTE SHEET (RULE 26)

2159103

31

(47) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25
(B) TYPE: nucleic acid
5 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 46:

GTACTGGGTC TCTCTGGTTA GACCA 25

(48) INFORMATION FOR SEQ ID NO: 47:

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 47:

CACACAACAG ACGGGCACAC ACTACTTG 28

(49) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25
20 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 48:

CTGAGGGATC TCTAGTTACC AGAGT 25

25 (50) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
30 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 49:

CTCTGGTAAC TAGAGATCCC TCA 23

(51) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23
35 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single

SUBSTITUTE SHEET (RULE 26)

2159103

32

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 50:
GTTCGGGCGC CACTGCTAGA GAT 23

(52) INFORMATION FOR SEQ ID NO: 51:

5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

10 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 51:
GCAAGCCGAGT CCTGCGTCG AGA 23

(53) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

15 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 52:
AATTTAATAC GACTCACTAT AGGGAGA 27

20 (54) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

25 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 53:
CCCATCTCTC TCCTTCTAGC CTCCGCTAGT C 31

(55) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 31

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 54:
35 CATGGGTATT ACTTCTGGGC TGAAAGCCTT C 31

(56) INFORMATION FOR SEQ ID NO: 55:

SUBSTITUTE SHEET (RULE 26)

2159103

33

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 30
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 55:

AGTGGGGGGA CATCAAGCAG CCATGCAAAT 30

(57) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 26
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 56:

15 GGCCAGATGA GAGAACCAAG GGGAAG 26

(58) INFORMATION FOR SEQ ID NO: 57:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 37
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 57:

CTACTAGTAC CCTTCAGGAA CAAATAGGAT GGATGAC 37

(59) INFORMATION FOR SEQ ID NO: 58:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

30 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 58:

CACTAGAAGA AATGATGACA GCATGTCAGG GAG 33

(60) INFORMATION FOR SEQ ID NO: 59:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 31
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

SUBSTITUTE SHEET (RULE 26)

2159103

34

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 59:
GGGATTAGAT ATCAGTACAA TGTGCTTCCA C 31

(61) INFORMATION FOR SEQ ID NO: 60:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 37
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 60:
10 TTAGAAATAG GGCAGCATAG AACAAAAATA GAGGAGC 37

(62) INFORMATION FOR SEQ ID NO: 61:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23
(B) TYPE: nucleic acid
15 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 61:
GCATGGGTAC CAGCACACAA AGG 23

(63) INFORMATION FOR SEQ ID NO: 62:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 62:
GGGGTACAGT GCAGGGGAAA GAATAGTAG 29

(64) INFORMATION FOR SEQ ID NO: 63:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29
30 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 63:
TTCCTGCCAT AGGAGATGCC TAAGGCTTT 29

35 (65) INFORMATION FOR SEQ ID NO: 64:

(i) SEQUENCE CHARACTERISTICS:

SUBSTITUTE SHEET (RULE 26)

2159103

35

(A) LENGTH: 28
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 64:
CCCTCAGATC CTGCATATAA GCAGCTGC 28

(66) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33
10 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 65:
CCCCTGCTT AAGCCTCAAT AAAGCTTGCC TTG 33

15 (67) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
20 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 66:
TCCCTGTTCG GCGCCACTG CTAGAGAT 28

(68) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31
25 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 67:
30 GACUAGCGGA GGCUAGAAGG AGAGAGAUGG G 31

(69) INFORMATION FOR SEQ ID NO: 68:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31
(B) TYPE: nucleic acid
35 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

SUBSTITUTE SHEET (RULE 26)

2159103

36

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 68:
GAAGGCUUUC AGCCCAGAAG UAAUACCCAU G 31

(70) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 30
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 69:
10 AUUUGCAUGG CUGCUUGAUG UCCCCCACU 30

(71) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26
(B) TYPE: nucleic acid
15 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 70:
CUUCCCCUUG GUUCUCUCAU CUGGCC 26

(72) INFORMATION FOR SEQ ID NO: 71:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 71:
GUCAUCCAUC CUAUUUGUUC CUGAAGGGUA CUAGUAG 37

(73) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33
30 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 72:
CUCCCUGACA UGCUGUCAUC AUUUCUUCUA GUG 33

35 (74) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31

SUBSTITUTE SHEET (RULE 26)

37

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 73:

5 GUGGAAGCAC AUUGUACUGA UAUCUAAUCC C 31

(75) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37
(B) TYPE: nucleic acid
10 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 74:

GCUCCUCUAU UUUUGUUCUA UGCUGCCCUA UUUCUAA 37

(76) INFORMATION FOR SEQ ID NO: 75:

15 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

20 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 75:

CCUUUGUGUG CUGGUACCCA UGC 23

(77) INFORMATION FOR SEQ ID NO: 76:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29
25 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 76:

CUACUAUUCU UCCCCUGCA CUGUACCCC 29

30 (78) INFORMATION FOR SEQ ID NO: 77:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
35 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 77:

AAAGCCUAG GCAUCUCCUA UGGCAGGAA 29

SUBSTITUTE SHEET (RULE 26)

2159103

38

(79) INFORMATION FOR SEQ ID NO: 78:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28
(B) TYPE: nucleic acid
5 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 78:

GCAGCUGCUU AUAUGCAGGA UCUGAGGG 28

(80) INFORMATION FOR SEQ ID NO: 79:

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 79:

CAAGGCAAGC UUUAUUGAGG CUUAAGCAGU GGG 33

(81) INFORMATION FOR SEQ ID NO: 80:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28
20 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 80:

AUCUCUAGCA GUGGCGCCCG AACAGGGA 28

25 (82) INFORMATION FOR SEQ ID NO: 81:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
30 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 81:

CCCAUCUCUC UCCUUCUAGC CUCCGCUAGU C 31

(83) INFORMATION FOR SEQ ID NO: 82:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31
35 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single

SUBSTITUTE SHEET (RULE 26)

2159103

39

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 82:
CAUGGGUAUU ACUUCUGGGC UGAAAGCCUU C 31

(84) INFORMATION FOR SEQ ID NO: 83:

5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

10 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 83:
AGUGGGGGGA CAUCAAGCAG CCAUGCAAA U 31

(85) INFORMATION FOR SEQ ID NO: 84:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

15 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 84:
GGCCAGAUGA GAGAACCAAG GGGAAG 26

20 (86) INFORMATION FOR SEQ ID NO: 85:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

25 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 85:
CUACUAGUAC CCUUCAGGAA CAAAUAGGAU GGAUGAC 37

(87) INFORMATION FOR SEQ ID NO: 86:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 33

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 86:
35 CACUAGAAGA AAUGAUGACA GCAUGUCAGG GAG 33

(88) INFORMATION FOR SEQ ID NO: 87:

SUBSTITUTE SHEET (RULE 26)

2159103

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
5 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 87:

GGGAUUAGAU AUCAGUACAA UGUGCUUCCA C 31

(89) INFORMATION FOR SEQ ID NO: 88:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 37
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 88:

15 UUAGAAAUAG GGCAGCAUAG AACAAAAUA GAGGAGC 37

(90) INFORMATION FOR SEQ ID NO: 89:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23
(B) TYPE: nucleic acid
20 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 89:

GCAUGGGUAC CAGCACACAA AGG 23

(91) INFORMATION FOR SEQ ID NO: 90:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

30 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 90:

GGGGUACAGU GCAGGGGAAA GAAUAGUAG 29

(92) INFORMATION FOR SEQ ID NO: 91:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29
35 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

SUBSTITUTE SHEET (RULE 26)

41

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 91:
UUCCUGCCAU AGGAGAUGCC UAAGGCUUU 29
(93) INFORMATION FOR SEQ ID NO: 92:
(i) SEQUENCE CHARACTERISTICS:
5 (A) LENGTH: 28
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 92:
10 CCCUCAGAU CUGCAUAUAA GCAGCUGC 28
(94) INFORMATION FOR SEQ ID NO: 93:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33
(B) TYPE: nucleic acid
15 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 93:
CCCACUGCUU AAGCCUCAAU AAAGCUUGCC UUG 33
(95) INFORMATION FOR SEQ ID NO: 94:
20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
25 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 94:
UCCCUGUUCG GCGCCACUG CUAGAGAU 38
(96) INFORMATION FOR SEQ ID NO: 95:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24
30 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 95:
CCGCTTAATA CTGACGCTCT CGCA 24
35 (97) INFORMATION FOR SEQ ID NO: 96:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36

SUBSTITUTE SHEET (RULE 26)

2159103

42

(B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 96:

5 GGGATGGAAA GGATCACCAG CAATATTCCA AAGTAG 36

(98) INFORMATION FOR SEQ ID NO: 97:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33
 (B) TYPE: nucleic acid
 10 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 97:

CATCCACAAT TTAAAAGAA AAGGGGGGAT TGG 33

(99) INFORMATION FOR SEQ ID NO: 98:

15 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

20 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 98:

TGGGCGGGAC TGGGGAGTGG CGAG 24

(100) INFORMATION FOR SEQ ID NO: 99:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24
 25 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 99:

CUCGACGCAG GACUCGGCUU GCUG 24

30 (101) INFORMATION FOR SEQ ID NO: 100:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 35 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 100:

CUCCCCCGCU UAAUACUGAC GCU 23

SUBSTITUTE SHEET (RULE 26)

2159103

43

(102) INFORMATION FOR SEQ ID NO: 101:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31

(B) TYPE: nucleic acid

5 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 101:

GGCAAUGGU ACAUCAGGCC AUAUCACCUA G 31

(103) INFORMATION FOR SEQ ID NO: 102:

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 102:

GGGGUGGCUC CUUCUGAUAA UGCUG 25

(104) INFORMATION FOR SEQ ID NO: 103:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

20 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 103:

CAGAAGGAGC CACCCACAA GAUUUA 26

25 (105) INFORMATION FOR SEQ ID NO: 104:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 104:

GACCAUCAAU GAGGAAGCUG CAGAAUG 27

(106) INFORMATION FOR SEQ ID NO: 105:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 25

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

SUBSTITUTE SHEET (RULE 26)

44

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 105:
CCCAUUCUGC AGCUUCCUCA UUGAU 25

(107) INFORMATION FOR SEQ ID NO: 106:

5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

10 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 106:
AGUGACAUAG CAGGAACUA 19

(108) INFORMATION FOR SEQ ID NO: 107:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26

15 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 107:
CCAUCCUAUU UGUUCCUGAA GGGUAC 26

20 (109) INFORMATION FOR SEQ ID NO: 108:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

25 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 108:
AGAUUUCUCC UACUGGGAUA GGU 23

(110) INFORMATION FOR SEQ ID NO: 109:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 30

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 109:
35 GAAACCUUGU UGAGUCCAAA AUGCGAACCC 30

(111) INFORMATION FOR SEQ ID NO: 110:

(i) SEQUENCE CHARACTERISTICS:

SUBSTITUTE SHEET (RULE 26)

45

(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 110:
UGUGCCCUUC UUUGCCAC 18

(112) INFORMATION FOR SEQ ID NO: 111:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22
10 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 111:
CAGUACUGGA UGUGGGUGAU GC 22

15 (113) INFORMATION FOR SEQ ID NO: 112:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
20 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 112:
GUCAUGCUAC UUUGGAAUUAU UUCUGGUGAU CCUUU 35

(114) INFORMATION FOR SEQ ID NO: 113:
(i) SEQUENCE CHARACTERISTICS:
25 (A) LENGTH: 33
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 113:
30 CAAUACAUGG AUGAUUUGUA UGUAGGAUCU GAC 33

(115) INFORMATION FOR SEQ ID NO: 114:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28
(B) TYPE: nucleic acid
35 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

SUBSTITUTE SHEET (RULE 26)

2159103

46

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 114:
ACCAAAGGAA UGGAGGUUCU UUCUGAUG 28

(116) INFORMATION FOR SEQ ID NO: 115:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 28
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 115:
10 GCAUUAGGAA UCAUUCAAGC ACAACCAG 28

(117) INFORMATION FOR SEQ ID NO: 116:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 34
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 116:
GCACUGACUA AUUUAUCUAC UUGUUCAUUU CCUC 34

(118) INFORMATION FOR SEQ ID NO: 117:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 117:
25 GGGAUUGGAG GAAUGAACA AGUAGAUAAA UUAGUCAG 38

(119) INFORMATION FOR SEQ ID NO: 118:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 35
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 118:
UGUGUACAAU CUAGUUGCCA UAUUCCUGGA CUACA 35

35 (120) INFORMATION FOR SEQ ID NO: 119:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

SUBSTITUTE SHEET (RULE 26)

2159103

47

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 119:
5 CAA AUGGCAG UAUUCAUCCA CA 22

(121) INFORMATION FOR SEQ ID NO: 120:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23
(B) TYPE: nucleic acid
10 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 120:
GUUUGUAUGU CUGUUGCUAU UAU 23

(122) INFORMATION FOR SEQ ID NO: 121:
15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 121:
20 CCCUUCACCU UCCAGAG 18

(123) INFORMATION FOR SEQ ID NO: 122:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27
25 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 122:
GAGCCUGGA AGCAUCCAGG AAGUCAG 27

30 (124) INFORMATION FOR SEQ ID NO: 123:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
35 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 123:
CUUCGUCGCU GUCUCCGCUU C 21

SUBSTITUTE SHEET (RULE 26)

48

(125) INFORMATION FOR SEQ ID NO: 124:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27
(B) TYPE: nucleic acid
5 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 124:

CAAGGGACUU UCCGCUGGGG ACUUUCC 27

(126) INFORMATION FOR SEQ ID NO: 125:

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

15 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 125:

GUCUAACCAG AGAGACCCAG UACAGGC 27

(127) INFORMATION FOR SEQ ID NO: 126:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25
20 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 126:

GUACUGGGUC UCUCUGGUUA GACCA 25

25 (128) INFORMATION FOR SEQ ID NO: 127:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
30 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 127:

CACACAACAG ACGGGCACAC ACUACUUG 28

(129) INFORMATION FOR SEQ ID NO: 128:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25
35 (B) TYPE: nucleic acid
(C) STRANDEDNESS: single

SUBSTITUTE SHEET (RULE 26)

2159103

49

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 128:
CUGAGGGAUC UCUAGUUACC AGAGU 25

(130) INFORMATION FOR SEQ ID NO: 129:

5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

10 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 129:
CUCUGGUAAC UAGAGAUCCC UCA 23

(131) INFORMATION FOR SEQ ID NO: 130:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

15 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 130:
GUUCGGGCGC CACUGCUAGA GAU 23

20 (132) INFORMATION FOR SEQ ID NO: 131:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

25 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 131:
GCAAGCCGAG UCCUGCGUCG AGA 23

(133) INFORMATION FOR SEQ ID NO: 132:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 24

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 132:
35 UGCGAGAGCG UCAGUAUUAA GCGG 24

(134) INFORMATION FOR SEQ ID NO: 133:

(i) SEQUENCE CHARACTERISTICS:

SUBSTITUTE SHEET (RULE 26)

2159103

50

(A) LENGTH: 36
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

5 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 133:
 CUACUUUGGA AUAUUGCUGG UGAUCCUUUC CAUCCC 36

(135) INFORMATION FOR SEQ ID NO: 134:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 33
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 134:
 CCAAUCCCCC CUUUUCUUUU AAAAUUGUGG AUG 33

15 (136) INFORMATION FOR SEQ ID NO: 135:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 24
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 135:
 CUCGCCACUC CCCAGUCCCCG CCA 24

(137) INFORMATION FOR SEQ ID NO: 136:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 24
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 136:
 30 CCGCUUAAUA CUGACGCUCU CGCA 24

(138) INFORMATION FOR SEQ ID NO: 137:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 36
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

SUBSTITUTE SHEET (RULE 26)

2159103

51

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 137:

GGGAUGGAAA GGAUCACCAG CAUAUUGCA AAGUAG 36

(139) INFORMATION FOR SEQ ID NO: 138:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 33
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 138:

10 CAUCCACAAU UUUAAAAGAA AAGGGGGGAU UGG 33

(140) INFORMATION FOR SEQ ID NO: 139:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 24
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 139:

UGGGCGGGAC UGGGAGUGG CGAG 24

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. An oligonucleotide of 23 to 100 nucleotides comprising a sequence selected from the group consisting of:

(SEQ ID NO: 5) GTCATCCATCCTATTTGTTCTGAAGGGTACTAGTAG,
 (SEQ ID NO: 6) CTCCTGACATGCTGTCATCATTTCTTCTAGTG,
 (SEQ ID NO: 7) GTGGAAGCACATTGTACTGATATCTAATCCC,
 (SEQ ID NO: 8) GTCCTCTATTTTTGTTCTATGCTGCCCTATTTCTAA,
 (SEQ ID NO: 13) CAAGGCAAGCTTTATTGAGGCTTAAGCAGTGGG,
 (SEQ ID NO: 14) ATCTCTAGCAGTGGCGCCCGAACAGGGA,
 (SEQ ID NO: 57) CTACTAGTACCCTTCAGGAACAAATAGGATGGATGAC,
 (SEQ ID NO: 58) CACTAGAAGAAATGATGACAGCATGTCAGGGAG,
 (SEQ ID NO: 59) GGGATTAGATATCAGTACAATGTGCTTCCAC,
 (SEQ ID NO: 60) TTAGAAATAGGGCAGCATAGAACAAAAATAGAGGAGC,
 (SEQ ID NO: 65) CCCACTGCTTAAGCCTCAATAAAGCTTGCCTTG,
 (SEQ ID NO: 66) TCCCTGTTCTGGGCGCCACTGCTAGAGAT,
 (SEQ ID NO: 71) GUCAUCCAUCCUAUUUGUCCUGAAGGGUACUAGUAG,
 (SEQ ID NO: 72) CUCCCUGACAUGCUGUCAUUAUUCUUCUAGUG,
 (SEQ ID NO: 73) GUGGAAGCACAUUGUACUGAUUAUCUAAUCCC,
 (SEQ ID NO: 74) GCUCCUCUAUUUUUGUUCUAUGCUGCCCUAUUUCUAA,
 (SEQ ID NO: 79) CAAGGCAAGCUUUAUUGAGGCUUAAGCAGUGGG,
 (SEQ ID NO: 80) AUCUCUAGCAGUGGGCGCCCGAACAGGGA,
 (SEQ ID NO: 85) CUACUAGUACCCUUCAGGAACAAAUAGGAUGGAUGAC,
 (SEQ ID NO: 86) CACUAGAAGAAAUGAUGACAGCAUGUCAGGGAG,
 (SEQ ID NO: 87) GGGAUUAGAUUAUCAGUACAAUGUGCUUCCAC,
 (SEQ ID NO: 88) UUAGAAAUAGGGCAGCAUAGAACAAAAAUAGAGGAGC,
 (SEQ ID NO: 93) CCCACUGCUUAAGCCUCAUAAAGCUUGCCUUG, and
 (SEQ ID NO: 94) UCCCUGUUCGGGCGCCACUGCUAGAGAU,

wherein under hybridization assay conditions said oligonucleotide hybridizes to a nucleic acid from HIV-1 to form a detectable probe:target duplex and does not hybridize to non-target nucleic acid from Human Immunodeficiency Virus type 2, Human T-Cell leukemia virus type 1, Human T-cell virus type 2, and Human Hepatitis B virus serotype ADW to form a detectable probe:non-target duplex indicating the presence of said non-target nucleic acid under said conditions.

2. The oligonucleotide of claim 1, wherein said oligonucleotide comprises a sequence selected from the group of: SEQ ID NO: 5, SEQ ID NO: 71, SEQ ID NO: 57, and SEQ ID NO: 85.

3. The oligonucleotide of claim 1, wherein said oligonucleotide comprises a sequence selected from the group consisting of: SEQ ID NO: 6, SEQ ID NO: 58, SEQ ID NO: 72, and SEQ ID NO: 86.

4. The oligonucleotide of claim 1, wherein said oligonucleotide comprises a sequence selected from the group consisting of: SEQ ID NO: 7, SEQ ID NO: 59, SEQ ID NO: 73, and SEQ ID NO: 87.

5. The oligonucleotide of claim 1, wherein said oligonucleotide comprises a sequence selected from the group consisting of: SEQ ID NO: 8, SEQ ID NO: 60, SEQ ID NO: 74, and SEQ ID NO: 88.

6. The oligonucleotide of claim 1, wherein said oligonucleotide comprises a sequence selected from the group consisting of: SEQ ID NO: 13, SEQ ID NO: 65, SEQ ID NO: 79, and SEQ ID NO: 93.

7. The oligonucleotide of claim 1, wherein said oligonucleotide comprises a sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 66, SEQ ID NO: 80, and SEQ ID NO: 94.

8. The oligonucleotide of any one of claims 1-7 wherein said oligonucleotide consists of said sequence and one or more optionally present labels.

9. The oligonucleotide of claim 8, wherein at least one detectable label is present.

10. The oligonucleotide of claim 9, wherein said at least one detectable label is an acridinium ester or a derivative thereof.

11. A probe mix comprising, an oligonucleotide detection probe comprising a sequence selected from the group consisting of: SEQ ID

NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, and SEQ ID NO: 94; wherein said detection probe hybridizes, under hybridization assay conditions, to a nucleic acid from HIV-1 to form a detectable probe:target duplex and does not hybridize to non-target nucleic acid from Human Immunodeficiency Virus type 2, Human T-Cell leukemia virus type 1, Human T-cell virus type 2, and Human Hepatitis B virus serotype ADW to form a detectable probe:non-target duplex indicating the presence of said non-target nucleic acid under said conditions;

an optionally present amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID Nos: 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, and 123; and

an optionally present helper oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID Nos: 15, 16, 17, 18, 95, 96, 97, 98, 132, 133, 134, 135, 136, 137, 138, and 139;

provided that at least one of said optionally present amplification oligonucleotide and said optionally present helper oligonucleotide is present.

12. A probe mix of claim 11, wherein said detection probe comprises a sequence selected from the group consisting of: SEQ ID NO: 3, SEQ ID NO: 55, SEQ ID NO: 69, and SEQ ID NO: 83, and said probe mix comprises a first amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 23 and SEQ ID NO: 103, and a second amplification oligonucleotide comprising a sequence

selected from the group consisting of: SEQ ID NO: 25 and SEQ ID NO: 105.

13. The probe mix of claim 12, wherein said detection probe consists of a detectable label and the sequence of SEQ ID NO: 3, said first amplification oligonucleotide consists of the sequence of SEQ ID NO: 23 joined at its 5' end to a sequence recognized by an RNA polymerase; and said second amplification oligonucleotide consists of the sequence of SEQ ID NO: 25.

14. The probe mix of claim 11, wherein said detection probe comprises a sequence selected from the group consisting of: SEQ ID NO: 5, SEQ ID NO: 57, SEQ ID NO: 71, and SEQ ID NO: 85; and said probe mix comprises a first amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 26 and SEQ ID NO: 106, and a second amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 28 and SEQ ID NO: 108.

15. The probe mix of claim 14, wherein said detection probe consists of a detectable label and the sequence of SEQ ID NO: 5; said first amplification oligonucleotide consists of the sequence of SEQ ID NO: 26 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO: 26; and said second amplification oligonucleotide consists of the sequence of SEQ ID NO: 28.

16. The probe mix of claim 11, wherein said detection probe comprises a sequence selected from the group consisting of: SEQ ID NO: 6, SEQ ID NO: 58, SEQ ID NO: 72, and SEQ ID NO: 86; and said probe mix comprises a first amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 29 and SEQ ID NO: 109, and a second amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 30 and SEQ ID NO: 110.

17. The probe mix of claim 16, wherein said detection probe consists of a detectable label and the sequence of SEQ ID NO: 6, said first amplification oligonucleotide consists of the sequence of SEQ ID NO: 29 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO: 29; and said second amplification oligonucleotide consists of the sequence of SEQ ID NO: 30.

18. The probe mix of claim 11, wherein said detection probe comprises a sequence selected from the group consisting of: SEQ ID NO: 7, SEQ ID NO: 59, SEQ ID NO: 73, and SEQ ID NO: 87; and said probe mix comprises a first amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 31 and SEQ ID NO: 111, and a second amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 32 and SEQ ID NO: 112.

19. The probe mix of claim 18, wherein said detection probe consists of a detectable label and the sequence of SEQ ID NO: 7, said first amplification oligonucleotide consists of the sequence of SEQ ID NO: 31 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO: 31; and said second amplification oligonucleotide consists of the sequence of SEQ ID NO: 32.

20. The probe mix of claim 19, further comprising the presence of a helper oligonucleotide, said helper oligonucleotide consisting of a sequence selected from the group consisting of: SEQ ID NO: 16 and SEQ ID NO: 133.

21. The probe mix of claim 11, wherein said detection probe comprises a sequence selected from the group consisting of: SEQ ID NO: 7, SEQ ID NO: 59, SEQ ID NO: 73, and SEQ ID NO: 87; and said probe mix comprises a helper oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 96, SEQ ID NO: 133, and SEQ ID NO: 137.

2159103

22. The probe mix of claim 21, wherein said detection probe consists of a detectable label and a sequence selected from the group consisting of: SEQ ID NO: 7 and SEQ ID NO: 73, and said helper oligonucleotide consists of a sequence selected from the group consisting of SEQ ID NO: 16, and SEQ ID NO: 133.

23. The probe mix of claim 11, wherein said detection probe comprises a sequence selected from the group consisting of: SEQ ID NO: 8, SEQ ID NO: 60, SEQ ID NO: 74, and SEQ ID NO: 88; and said probe mix comprises a first amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 33 and SEQ ID NO: 113, and a second amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 34 and SEQ ID NO: 114.

24. The probe mix of claim 23, wherein said detection probe consists of a detectable label and the sequence of SEQ ID NO: 8, said first amplification oligonucleotide consists of the sequence of SEQ ID NO: 33 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO: 33; and said second amplification oligonucleotide consists of the sequence of SEQ ID NO: 34.

25. The probe mix of claim 11, wherein said detection probe comprises a sequence selected from the group consisting of: SEQ ID NO: 9, SEQ ID NO: 61, SEQ ID NO: 75, and SEQ ID NO: 89; and said probe mix comprises a first amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 35 and SEQ ID NO: 115, and a second amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 36 and SEQ ID NO: 116.

26. The probe mix of claim 25, wherein said detection probe consists of a detectable label and the sequence of SEQ ID NO: 9, said first amplification oligonucleotide consists of the sequence of SEQ ID NO: 35 and a sequence recognized by an RNA polymerase joined to the 5'

end of SEQ ID NO: 35; and said second amplification oligonucleotide consists of the sequence of SEQ ID NO: 36.

27. The probe mix of claim 11, wherein said detection probe comprises a sequence selected from the group consisting of: SEQ ID NO: 11, SEQ ID NO: 63, SEQ ID NO: 77, and SEQ ID NO: 91, and said probe mix comprises a first amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 42 and SEQ ID NO: 122, and a second amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 43 and SEQ ID NO: 123.

28. The probe mix of claim 27, wherein said detection probe consists of a detectable label and the sequence of SEQ ID NO: 11, said first amplification oligonucleotide consists of the sequence of SEQ ID NO: 43 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO: 43; and said second amplification oligonucleotide consists of the sequence of SEQ ID NO: 42.

29. The probe mix of claim 11, wherein said detection probe comprises a sequence selected from the group consisting of: SEQ ID NO: 13, SEQ ID NO: 65, SEQ ID NO: 79, and SEQ ID NO: 93, and said probe mix comprises a first amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 46 and SEQ ID NO: 126, and a second amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 127, SEQ ID NO: 128 and SEQ ID NO: 130.

30. The probe mix of claim 11, wherein said detection probe comprises a sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 66, SEQ ID NO: 80, and SEQ ID NO: 94, and said probe mix comprises a first amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 49 and SEQ ID NO: 129, and a second amplification oligonucleotide comprising a

sequence selected from the group consisting of: SEQ ID NO: 51 and SEQ ID NO: 131.

31. A probe mix of comprising:

a detection probe comprising a sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 53, SEQ ID NO: 67, and SEQ ID NO: 81;

an optionally present helper oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 95, SEQ ID NO: 132, and SEQ ID NO: 136;

and an optionally present amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 99, and SEQ ID NO: 100;

wherein at least one of said optionally present amplification oligonucleotide and said optionally present helper oligonucleotide is present.

32. The probe mix of claim 31, comprising a helper oligonucleotide consisting of a sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 95, SEQ ID NO: 132, and SEQ ID NO: 136.

33. The probe mix of claim 32, wherein said detection probe consists of a detectable label and the sequence of either SEQ ID NO: 1 or SEQ ID NO: 67, and said helper oligonucleotide consists of the sequence of either SEQ ID NO: 15 or SEQ ID NO: 132.

34. The probe mix claim 33, wherein said detection probe consists of said detectable label and the sequence of SEQ ID NO: 1, said helper oligonucleotide consists of the sequence of SEQ ID NO: 15, and said probe mix further comprises a first amplification oligonucleotide consisting of the sequence of SEQ ID NO: 19 and a second amplification oligonucleotide consists of the sequence of SEQ ID NO: 20 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO: 20.

35. A probe mix of comprising:

a detection probe comprising a sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 54, SEQ ID NO: 68, and SEQ ID NO: 82; and

an amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 101, and SEQ ID NO: 102.

36. The probe mix claim 35, wherein said detection probe consists of a detectable label and the sequence of SEQ ID NO: 2, and said probe mix comprises a first amplification oligonucleotide consisting of the sequence of SEQ ID NO: 21 and a second amplification oligonucleotide consisting of the sequence of SEQ ID NO: 22 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO: 22.

37. A probe mix of comprising:

a detection probe comprising a sequence selected from the group consisting of: SEQ ID NO: 4, SEQ ID NO: 56, SEQ ID NO: 70, and SEQ ID NO: 84; and

an amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 104, and SEQ ID NO: 107.

38. The probe mix claim 37, wherein said detection probe consists of a detectable label and the sequence of SEQ ID NO: 4, and said probe mix comprises a first amplification oligonucleotide consisting of the sequence of SEQ ID NO: 27 and a second amplification oligonucleotide consisting of the sequence of SEQ ID NO: 24 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO: 24.

39. A probe mix of comprising:

a detection probe comprising a sequence selected from the group consisting of: SEQ ID NO: 10, SEQ ID NO: 62, SEQ ID NO: 76, and SEQ ID NO: 90;

an optionally present helper oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 97, SEQ ID NO: 134, and SEQ ID NO: 138;

and an optionally present amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 119, SEQ ID NO: 120, and SEQ ID 121;

wherein at least one of said optionally present amplification oligonucleotide and said optionally present helper oligonucleotide is present.

40. The probe mix of claim 39, comprising a helper oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 97, SEQ ID NO: 134, and SEQ ID NO: 138.

41. The probe mix of claim 40, wherein said detection probe consists of a detectable label and the sequence of either SEQ ID NO: 10 or SEQ ID NO: 76, and said helper oligonucleotide consists of the sequence of either SEQ ID NO: 17 or SEQ ID NO: 134.

42. The probe mix claim 41, wherein said detection probe consists of said detectable label and the sequence of SEQ ID NO: 10, said helper oligonucleotide consists of the sequence of SEQ ID NO: 17, and said probe mix further comprises a first amplification oligonucleotide consisting of either the sequence of SEQ ID NO: 40 or SEQ ID NO: 41, and a second amplification oligonucleotide consists of the sequence of SEQ ID NO: 39 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO: 39.

43. A probe mix of comprising

a detection probe comprising a sequence selected from the group consisting of: SEQ ID NO: 12, SEQ ID NO: 64, SEQ ID NO: 78, and SEQ ID NO: 92;

an optionally present helper oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 18, SEQ ID NO: 98, SEQ ID NO: 135, and SEQ ID NO: 139;

and an optionally present amplification oligonucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 124, and SEQ ID NO: 125;

wherein at least one of said optionally present amplification oligonucleotide and said optionally present helper oligonucleotide is present.

44. The probe mix of claim 43, comprising a helper oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 98, SEQ ID NO: 135, and SEQ ID NO: 139.

45. The probe mix of claim 44, wherein said detection probe consists of a detectable label and the sequence of either SEQ ID NO: 12 or SEQ ID NO: 78, and said helper oligonucleotide consists of either SEQ ID NO: 18 or SEQ ID NO: 135.

46. The probe mix claim 45, wherein said detection probe consists of said detectable label and the sequence of SEQ ID NO: 12, said helper oligonucleotide consists of the sequence of SEQ ID NO: 18, and said probe mix further comprises a first amplification oligonucleotide consisting of the sequence of sequence of SEQ ID NO: 45 and a second amplification oligonucleotide consists of the sequence of SEQ ID NO: 44 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO: 44.

47. A method for determining whether HIV-1 is present in a sample and distinguishing the presence of HIV-1 from HIV-2 comprising the steps of,

a) contacting said sample with a hybridization assay detection probe comprising a nucleotide base sequence for specifically detecting an HIV-1 target sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 53, SEQ ID NO 54, SEQ ID NO 55, SEQ ID NO 56, SEQ ID NO 57, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 60, SEQ ID NO 61, SEQ ID NO 62, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 66, SEQ ID NO 67, SEQ ID NO 68, SEQ ID NO 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 73, SEQ ID NO 74, SEQ ID NO 75, SEQ ID NO 76, SEQ ID NO 78, SEQ ID NO 79, SEQ ID NO 80, SEQ ID NO 81, SEQ ID NO 82, SEQ ID NO 83, SEQ ID NO 84, SEQ ID NO 85, SEQ ID NO 86, SEQ ID NO 87, SEQ ID NO 88, SEQ ID NO 89, SEQ ID NO 90, SEQ ID NO 92, SEQ ID NO 93, and SEQ ID NO 94; and

b) measuring the ability of said detection probe to detect the presence of said target sequence as an indication that HIV-1 and not HIV-2 is present in said sample.

48. The method of claim 47, wherein said target sequence is selected from the group consisting of SEQ ID NO 1, SEQ ID NO 53, SEQ ID NO 67, and SEQ ID NO 81.

49. The method of claim 47, wherein said target sequence is selected from the group consisting of SEQ ID NO 2, SEQ ID NO 54, SEQ ID NO 68, and SEQ ID NO 82.

50. The method of claim 47, wherein said target sequence is selected from the group consisting of SEQ ID NO 3, SEQ ID NO 55,

SEQ ID NO 69, and SEQ ID NO 83.

51. The method of claim 47, wherein said target sequence is selected from the group consisting of SEQ ID NO 4, SEQ ID NO 56, SEQ ID NO 70, and SEQ ID NO 84.

52. The method of claim 47, wherein said target sequence is selected from the group consisting of SEQ ID NO 5, SEQ ID NO 57, SEQ ID NO 71, and SEQ ID NO 85.

53. The method of claim 47, wherein said target sequence is selected from the group consisting of SEQ ID NO 6, SEQ ID NO 58, SEQ ID NO 72, and SEQ ID NO 86.

54. The method of claim 47, wherein said target sequence is selected from the group consisting of SEQ ID NO 7, SEQ ID NO 59, SEQ ID NO 73, and SEQ ID NO 87.

55. The method of claim 47, wherein said target sequence is selected from the group consisting of SEQ ID NO 8, SEQ ID NO 60, SEQ ID NO 74, and SEQ ID NO 88.

56. The method of claim 47, wherein said target sequence is selected from the group consisting of SEQ ID NO 9, SEQ ID NO 61, SEQ ID NO 75, and SEQ ID NO 89.

57. The method of claim 47, wherein said target sequence is selected from the group consisting of SEQ ID NO 10, SEQ ID NO 62, SEQ ID NO 76, and SEQ ID NO 90.

58. The method of claim 47, wherein said target sequence is selected from the group consisting of SEQ ID NO 12, SEQ ID NO 64, SEQ ID NO 78, and SEQ ID NO 92.

59. The method of claim 47, wherein said target sequence is selected from the group consisting of SEQ ID NO 13, SEQ ID NO 65, SEQ ID NO 79, and SEQ ID NO 93.

60. The method of claim 47, wherein said target sequence is selected from the group consisting of SEQ ID NO 14, SEQ ID NO 66, SEQ ID NO 80, and SEQ ID NO 94.

61. A method for determining whether HIV-1 is present in a sample and distinguishing the presence of HIV-1 from HIV-2 comprising the steps of,

a) contacting said sample with a hybridization assay detection probe comprising a nucleotide base sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 12, SEQ ID NO 13, SEQ ID NO 14, SEQ ID NO 53, SEQ ID NO 54, SEQ ID NO 55, SEQ ID NO 56, SEQ ID NO 57, SEQ ID NO 58, SEQ ID NO 59, SEQ ID NO 60, SEQ ID NO 61, SEQ ID NO 62, SEQ ID NO 64, SEQ ID NO 65, SEQ ID NO 66, SEQ ID NO 67, SEQ ID NO 68, SEQ ID NO 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 73, SEQ ID NO 74, SEQ ID NO 75, SEQ ID NO 76, SEQ ID NO 78, SEQ ID NO 79, SEQ ID NO 80, SEQ ID NO 81, SEQ ID NO 82, SEQ ID NO 83, SEQ ID NO 84, SEQ ID NO 85, SEQ ID NO 86, SEQ ID NO 87, SEQ ID NO 88, SEQ ID NO 89, SEQ ID NO 90, SEQ ID NO 92, SEQ ID NO 93, and SEQ ID NO 94;

wherein under hybridization assay conditions said detection probe hybridizes to a nucleic acid from HIV-1 to form a detectable probe:target duplex and does not hybridize to non-target nucleic acid from Human Immunodeficiency Virus type 2, Human T-Cell leukemia virus type 1, Human T-cell virus type 2, and Human Hepatitis B virus serotype ADW to form a detectable probe:non-target duplex indicating the presence of said non-target nucleic acid under said conditions, and

b) measuring the ability of said detection probe to hybridize to nucleic acid present in said sample as an indication that HIV-1 and not HIV-2 is present in said sample.

62. The method of claim 61, wherein said nucleotide base sequence is selected from the group consisting of SEQ ID NO 1, SEQ ID NO 53, SEQ ID NO 67, and SEQ ID NO 81.

63. The method of claim 62, wherein said detection probe consists of an optionally labeled oligonucleotide, provided that the base sequence of said optionally labeled oligonucleotide consists of a detection probe nucleotide base sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 53, SEQ ID NO 67, and SEQ ID NO 81.

64. The method of claim 63, wherein said detection probe comprises a reporter group label.

65. The method of claim 64, wherein said step (a) further comprises providing to said sample one or more helper oligonucleotides consisting of a nucleotide base sequence selected from the group consisting of SEQ ID NO 15, SEQ ID NO 95, SEQ ID NO 132, and SEQ ID NO 136.

66. The method of claim 65, further comprising the step of amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 19 and SEQ ID NO 99; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 20 and SEQ ID NO 100.

67. The method of claim 66, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 20 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ

ID NO 20; said second amplification oligonucleotide consists of the sequence of SEQ ID NO 19; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 1.

68. The method of claim 61, wherein said nucleotide base sequence is selected from the group consisting of SEQ ID NO 2, SEQ ID NO 54, SEQ ID NO 68, and SEQ ID NO 82.

69. The method of claim 68, wherein said detection probe consists of an optionally labeled oligonucleotide, provided that the base sequence of said optionally labeled oligonucleotide consists of a detection probe nucleotide base sequence selected from the group consisting of SEQ ID NO 2, SEQ ID NO 54, SEQ ID NO 68, and SEQ ID NO 82.

70. The method of claim 69, wherein said detection probe comprises a reporter group label.

71. The method of claim 70, further comprising the step of amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 21 and SEQ ID NO 101; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 22 and SEQ ID NO 102.

72. The method of claim 71, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 21; said second amplification oligonucleotide consists of the sequence of SEQ ID NO 22 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO 22; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 2.

73. The method of claim 61, wherein said nucleotide base sequence is selected from the group consisting of SEQ ID NO 3, SEQ ID NO 55, SEQ ID NO 69, and SEQ ID NO 83.

74. The method of claim 73, wherein said detection probe consists of an optionally labeled oligonucleotide, provided that the base sequence of said optionally labeled oligonucleotide consists of a detection probe nucleotide base sequence selected from the group consisting of SEQ ID NO 3, SEQ ID NO 55, SEQ ID NO 69, and SEQ ID NO 83.

75. The method of claim 74, wherein said detection probe comprises a reporter group label.

76. The method of claim 75, further comprising the step of amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 23 and SEQ ID NO 103; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 25 and SEQ ID NO 105.

77. The method of claim 76, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 23 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO 23; said second amplification oligonucleotide consists of the sequence of SEQ ID NO 25; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 3.

78. The method of claim 61, wherein said nucleotide base sequence is selected from the group consisting of SEQ ID NO 4, SEQ ID NO 56, SEQ ID NO 70, and SEQ ID NO 84.

79. The method of claim 78, wherein said detection probe consists of an optionally labeled oligonucleotide, provided that the

base sequence of said optionally labeled oligonucleotide consists of a detection probe nucleotide base sequence selected from the group consisting of SEQ ID NO 4, SEQ ID NO 56, SEQ ID NO 70, and SEQ ID NO 84.

80. The method of claim 79, wherein said detection probe comprises a reporter group label.

81. The method of claim 80, further comprising the step of amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 24 and SEQ ID NO 104; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 27 and SEQ ID NO 107.

82. The method of claim 81, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 27; said second amplification oligonucleotide consists of the sequence of SEQ ID NO 24 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO 24; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 4.

83. The method of claim 61, wherein said nucleotide base sequence is selected from the group consisting of SEQ ID NO 5, SEQ ID NO 57, SEQ ID NO 71, and SEQ ID NO 85.

84. The method of claim 83, wherein said detection probe consists of an optionally labeled oligonucleotide, provided that the base sequence of said optionally labeled oligonucleotide consists of a detection probe nucleotide base sequence selected from the group consisting of SEQ ID NO 5, SEQ ID NO 57, SEQ ID NO 71, and SEQ ID NO 85.

85. The method of claim 84, wherein said detection probe comprises a reporter group label.

86. The method of claim 85, further comprising the step of amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 26 and SEQ ID NO 106; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 28 and SEQ ID NO 108.

87. The method of claim 86, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 26 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO 26; said second amplification oligonucleotide consists of the sequence of SEQ ID NO 28; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 5.

88. The method of claim 61, wherein said nucleotide base sequence is selected from the group consisting of SEQ ID NO 6, SEQ ID NO 58, SEQ ID NO 72, and SEQ ID NO 86.

89. The method of claim 88, wherein said detection probe consists of an optionally labeled oligonucleotide, provided that the base sequence of said optionally labeled oligonucleotide consists of a detection probe nucleotide base sequence selected from the group consisting of SEQ ID NO 6, SEQ ID NO 58, SEQ ID NO 72, and SEQ ID NO 86.

90. The method of claim 89, wherein said detection probe comprises a reporter group label.

91. The method of claim 90, further comprising the step of amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected from the group

consisting of SEQ ID NO 29 and SEQ ID NO 109; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 30 and SEQ ID NO 110.

92. The method of claim 91, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 29 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO 29; said second amplification oligonucleotide consists of the sequence of SEQ ID NO 30; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 6.

93. The method of claim 61, wherein said nucleotide base sequence is selected from the group consisting of SEQ ID NO 7, SEQ ID NO 59, SEQ ID NO 73, and SEQ ID NO 87.

94. The method of claim 93, wherein said detection probe consists of an optionally labeled oligonucleotide, provided that the base sequence of said optionally labeled oligonucleotide consists of a detection probe nucleotide base sequence selected from the group consisting of SEQ ID NO 7, SEQ ID NO 59, SEQ ID NO 73, and SEQ ID NO 87.

95. The method of claim 94, wherein said detection probe comprises a reporter group label.

96. The method of claim 95, wherein said step (a) further comprises providing to said sample one or more helper oligonucleotides consisting of a nucleotide base sequence selected from the group consisting of SEQ ID NO 16, SEQ ID NO 96, SEQ ID NO 133, and SEQ ID NO 137.

97. The method of claim 95, wherein said method further comprises the step of amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected

from the group consisting of SEQ ID NO 31 and SEQ ID NO 111; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 32 and SEQ ID NO 112.

98. The method of claim 97, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 31 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO 31; said second amplification oligonucleotide consists of the sequence of SEQ ID NO 32; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 7.

99. The method of claim 61, wherein said nucleotide base sequence is selected from the group consisting of SEQ ID NO 8, SEQ ID NO 60, SEQ ID NO 74, and SEQ ID NO 88.

100. The method of claim 99, wherein said detection probe consists of an optionally labeled oligonucleotide, provided that the base sequence of said optionally labeled oligonucleotide consists of a detection probe nucleotide base sequence selected from the group consisting of SEQ ID NO 8, SEQ ID NO 60, SEQ ID NO 74, and SEQ ID NO 88.

101. The method of claim 100, wherein said detection probe comprises a reporter group label.

102. The method of claim 101, further comprising the step of amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 33 and SEQ ID NO 113; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 34 and SEQ ID NO 114.

103. The method of claim 102, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 33 and a

sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO 33; said second amplification oligonucleotide consists of the sequence of SEQ ID NO 34; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 8.

104. The method of claim 61, wherein said nucleotide base sequence is selected from the group consisting of SEQ ID NO 9, SEQ ID NO 61, SEQ ID NO 75, and SEQ ID NO 89.

105. The method of claim 104, wherein said detection probe consists of an optionally labeled oligonucleotide, provided that the base sequence of said optionally labeled oligonucleotide consists of a detection probe nucleotide base sequence selected from the group consisting of SEQ ID NO 9, SEQ ID NO 61, SEQ ID NO 75, and SEQ ID NO 89.

106. The method of claim 105, wherein said detection probe comprises a reporter group label.

107. The method of claim 106, further comprising the step of amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 35 and SEQ ID NO 115; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 36 and SEQ ID NO 116.

108. The method of claim 107, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 35 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO 35; said second amplification oligonucleotide consists of the sequence of SEQ ID NO 36; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 9.

109. The method of claim 61, wherein said nucleotide base sequence is selected from the group consisting of SEQ ID NO 10, SEQ ID NO 62, SEQ ID NO 76, and SEQ ID NO 90.

110. The method of claim 109, wherein said detection probe consists of an optionally labeled oligonucleotide, provided that the base sequence of said optionally labeled oligonucleotide consists of a detection probe nucleotide base sequence selected from the group consisting of SEQ ID NO 10, SEQ ID NO 62, SEQ ID NO 76, and SEQ ID NO 90.

111. The method of claim 110, wherein said detection probe comprises a reporter group label.

112. The method of claim 111, wherein said step (a) further comprises providing to said sample one or more helper oligonucleotides consisting of a nucleotide base sequence selected from the group consisting of SEQ ID NO 17, SEQ ID NO 97, SEQ ID NO 134, and SEQ ID NO 138.

113. The method of claim 111, further comprising the step of amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 39 and SEQ ID NO 119; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 40, SEQ ID NO 41, SEQ ID NO 120, and SEQ ID NO 121.

114. The method of claim 113, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 39 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO 39; said second amplification oligonucleotide consists of either the sequence of SEQ ID NO 40 or SEQ ID NO 41; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 10.

115. The method of claim 61, wherein said nucleotide base sequence is selected from the group consisting of SEQ ID NO 12, SEQ ID NO 64, SEQ ID NO 78, and SEQ ID NO 92.

116. The method of claim 115, wherein said detection probe consists of an optionally labeled oligonucleotide, provided that the base sequence of said optionally labeled oligonucleotide consists of a detection probe nucleotide base sequence selected from the group consisting of SEQ ID NO 12, SEQ ID NO 64, SEQ ID NO 78, and SEQ ID NO 92.

117. The method of claim 116, wherein said detection probe comprises a reporter group label.

118. The method of claim 116, wherein said step (a) further comprises providing to said sample one or more helper oligonucleotides consisting of a nucleotide base sequence selected from the group consisting of SEQ ID NO 18, SEQ ID NO 98, SEQ ID NO 135, and SEQ ID NO 139.

119. The method of claim 116, further comprising the step of amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 44 and SEQ ID NO 124; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 45 and SEQ ID NO 125.

120. The method of claim 119, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 44 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO 44; said second amplification oligonucleotide consists of the sequence of SEQ ID NO 45; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 12.

121. The method of claim 61, wherein said nucleotide base sequence is selected from the group consisting of SEQ ID NO 13, SEQ ID NO 65, SEQ ID NO 79, and SEQ ID NO 93.

122. The method of claim 121, wherein said detection probe consists of an optionally labeled oligonucleotide, provided that the base sequence of said optionally labeled oligonucleotide consists of a detection probe nucleotide base sequence selected from the group consisting of SEQ ID NO 13, SEQ ID NO 65, SEQ ID NO 79, and SEQ ID NO 93.

123. The method of claim 122, wherein said detection probe comprises a reporter group label.

124. The method of claim 123, further comprising the step of amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 46 and SEQ ID NO 126; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 47, SEQ ID NO 48, SEQ ID NO 50, SEQ ID NO 127, SEQ ID NO 128 and SEQ ID NO 130.

125. The method of claim 124, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 46; said second amplification oligonucleotide consists of either the sequence of SEQ ID NO 47, SEQ ID NO 48, or SEQ ID NO 50; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 13.

126. The method of claim 61, wherein said nucleotide base sequence is selected from the group consisting of SEQ ID NO 14, SEQ ID NO 66, SEQ ID NO 80, and SEQ ID NO 94.

127. The method of claim 126, wherein said detection probe consists of an optionally labeled oligonucleotide, provided that the base sequence of said optionally labeled oligonucleotide consists of a detection probe nucleotide base sequence selected from the group consisting of SEQ ID NO 14, SEQ ID NO 66, SEQ ID NO 80, and SEQ ID NO 94.

128. The method of claim 127, further comprising the step of amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 49 and SEQ ID NO 129; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 51 and SEQ ID NO 131.

129. The method of claim 128, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 49; said second amplification oligonucleotide consists of the sequence of SEQ ID NO 51; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 14.

130. A method for determining whether HIV-1 is present in a sample and distinguishing the presence of HIV-1 from HIV-2 comprising the steps of,

a) amplifying HIV-1 nucleic acid, if present, using a first amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 42 and SEQ ID NO 122; and a second amplification oligonucleotide comprising a sequence selected from the group consisting of SEQ ID NO 43 and SEQ ID NO 123.

b) contacting said sample with a hybridization assay detection probe comprising a nucleotide base sequence selected from the group consisting of; SEQ ID NO 11, SEQ ID NO 63, SEQ ID NO 77, and SEQ ID NO 91;

wherein under hybridization assay conditions said detection probe hybridizes to a nucleic acid from HIV-1 to form a detectable probe:target duplex and does not hybridize to non-target nucleic acid from Human Immunodeficiency Virus type 2, Human T-Cell leukemia virus

type 1, Human T-cell virus type 2, and Human Hepatitis B virus serotype ADW to form a detectable probe:non-target duplex indicating the presence of said non-target nucleic acid under said conditions,

c) measuring the ability of said detection probe to hybridize to nucleic acid present in said sample as an indication that HIV-1 and not HIV-2 is present in said sample.

131. The method of claim 130, wherein said detection probe comprises a reporter group label.

132. The method of claim 130, wherein said first amplification oligonucleotide consists of the sequence of SEQ ID NO 43 and a sequence recognized by an RNA polymerase joined to the 5' end of SEQ ID NO 43; said second amplification oligonucleotide consists of the sequence of SEQ ID NO 42; and said detection probe nucleotide base sequence consists of the sequence of SEQ ID NO 11.

SMART & BIGGAR
OTTAWA, CANADA

PATENT AGENTS